Cleveland Biolabs Inc (NASDAQ:CBLI): Institutional Investor Sentiment Up to 1.25

Cleveland BioLabs, Inc. (NASDAQ:CBLI) Logo

Sentiment for Cleveland Biolabs Inc (NASDAQ:CBLI)

Cleveland Biolabs Inc (NASDAQ:CBLI) institutional sentiment increased to 1.25 in Q2 2019. Its up 0.75, from 0.5 in 2019Q1. The ratio is more positive, as 5 investment managers increased or opened new equity positions, while 4 decreased and sold positions in Cleveland Biolabs Inc. The investment managers in our partner’s database now possess: 382,777 shares, down from 434,598 shares in 2019Q1. Also, the number of investment managers holding Cleveland Biolabs Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 3 Increased: 4 New Position: 1.

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The company has market cap of $11.86 million. The companyÂ’s advanced product candidate is entolimod, a Toll-like receptor 5 agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It currently has negative earnings. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand.

The stock increased 2.94% or $0.03 during the last trading session, reaching $1.05. About 5,623 shares traded. Cleveland BioLabs, Inc. (NASDAQ:CBLI) has declined 36.08% since September 13, 2018 and is downtrending. It has underperformed by 36.08% the S&P500.

Bank Of America Corp De holds 0% of its portfolio in Cleveland BioLabs, Inc. for 550 shares. Bank Of Montreal Can owns 31 shares or 0% of their US portfolio. Moreover, Blackrock Inc. has 0% invested in the company for 4,395 shares. The Massachusetts-based Geode Capital Management Llc has invested 0% in the stock. Renaissance Technologies Llc, a New York-based fund reported 303,316 shares.

More notable recent Cleveland BioLabs, Inc. (NASDAQ:CBLI) news were published by: Nasdaq.com which released: “Health Care Sector Update for 06/25/2015: GKOS,CBLI,BPMX – Nasdaq” on June 25, 2015, also Seekingalpha.com with their article: “Midatech Pharma leads healthcare gainers; TrovaGene and Cleveland BioLabs among losers – Seeking Alpha” published on April 24, 2019, Finance.Yahoo.com published: “Some Cleveland BioLabs (NASDAQ:CBLI) Shareholders Have Taken A Painful 83% Share Price Drop – Yahoo Finance” on August 20, 2019. More interesting news about Cleveland BioLabs, Inc. (NASDAQ:CBLI) were released by: Seekingalpha.com and their article: “Cleveland BioLabs up 27% on advancement of entolimod application – Seeking Alpha” published on March 07, 2019 as well as Seekingalpha.com‘s news article titled: “Healthcare names top midday movers – Seeking Alpha” with publication date: March 07, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.